OmniAb Results Presentation Deck
Active Clinical Programs and Approved Products
TWO NEW CLINICAL ENTRANTS IN Q2 2023
30
25
20
15
10
5
0
Number of Active
Clinical Programs and
Approved Products
2016
2017
2018
2019
2020
2021
2022
6/30/2023
●
●
●
2 new programs entered the clinic in Q2
IMVT-1402 (Immunovant): Next-generation FcRn antagonist
GLS-012 (Gloria): anti-LAG-3
3 new programs have entered the clinic so far in the first half of 2023
Based on dialog with our partners, we see potential for 1-2 additional
new entries into clinical development for novel OmniAb-derived
antibodies in the second half of 2023
Partner progression also continuing to show the flexibility of our
platform, with an increasing number of formats and modalities in clinical
or preclinical development
9
OmniAbView entire presentation